Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 109: | Line 109: | ||
PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549 | PMID:25965575; PMID:21627842; PMID:24939246; PMID:22516549 | ||
|- | |- | ||
| | |||
|Classic ependymoma (no WHO grade assigned) | |||
|'''Gain:''' 1q, 5, 7, 9, 11, 18, 20<br> | |||
'''Loss:''' 1p, 3, -6/6q, 9p, 13q, 17, 22 | |||
|Usually intracranial, spinal tumors (myxopapillary) are rare; 80% of pediatric tumors develop in posterior fossa (PF); Supratentorial tumors preferentially show monosomy 9; 1q gain is unfavorable prognostic indicator in PF tumors; spinal tumors associated with NF2 (germline); children have worse outcomes than adults | |||
|PMID:25965575; PMID:22338015; PMID:28371821 | |||
|- | |||
| | |||
|Subependymoma, WHO grade I | |||
|Typically '''balanced genomes'''<br> | |||
'''Loss:''' -6/6q in spinal tumors | |||
|No diagnostic mutations | |||
|Favorable prognosis | |||
|WHO CNS Tumors (2016) <br> | |||
PMID:21959044; PMID:21840481<br> | |||
|- | |||
| | |||
|Myxopapillary ependymoma, WHO grade I | |||
|'''Aneuploidy:''' multiple chromosomes lost and gained | |||
|'''Mutation:''' NF2 (including germline) in spinal tumors | |||
|Less common but more aggressive in children | |||
|PMID:25965575; PMCID:3991130; PMID:20425037; PMID:25957288; PMID:25965575; PMID:22516549 | |||
|- | |||
| | |||
| | |||